- Home
- SNPX vs HTLD Comparison
SNPX vs HTLD Comparison
Compare SNPX & HTLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNPX
- HTLD
- Stock Information
- Founded
- SNPX 2012
- HTLD 1978
- Country
- SNPX United States
- HTLD United States
- Employees
- SNPX 5
- HTLD N/A
- Industry
- SNPX Medicinal Chemicals and Botanical Products
- HTLD Trucking Freight/Courier Services
- Sector
- SNPX Health Care
- HTLD Industrials
- Exchange
- SNPX Nasdaq
- HTLD Nasdaq
- Market Cap
- SNPX 3.3M
- HTLD N/A
- IPO Year
- SNPX N/A
- HTLD N/A
- Fundamental
- Price
- SNPX $2.43
- HTLD $9.30
- Analyst Decision
- SNPX Strong Buy
- HTLD Sell
- Analyst Count
- SNPX 1
- HTLD 3
- Target Price
- SNPX $14.00
- HTLD $11.00
- AVG Volume (30 Days)
- SNPX 7.8K
- HTLD 477.3K
- Earning Date
- SNPX 05-14-2025
- HTLD 04-22-2025
- Dividend Yield
- SNPX N/A
- HTLD 0.86%
- EPS Growth
- SNPX N/A
- HTLD N/A
- EPS
- SNPX N/A
- HTLD N/A
- Revenue
- SNPX N/A
- HTLD $1,047,511,000.00
- Revenue This Year
- SNPX N/A
- HTLD $0.24
- Revenue Next Year
- SNPX N/A
- HTLD $7.05
- P/E Ratio
- SNPX N/A
- HTLD N/A
- Revenue Growth
- SNPX N/A
- HTLD N/A
- 52 Week Low
- SNPX $2.15
- HTLD $9.10
- 52 Week High
- SNPX $6.22
- HTLD $13.67
- Technical
- Relative Strength Index (RSI)
- SNPX 35.26
- HTLD 36.27
- Support Level
- SNPX $2.15
- HTLD $9.14
- Resistance Level
- SNPX $2.78
- HTLD $9.55
- Average True Range (ATR)
- SNPX 0.17
- HTLD 0.21
- MACD
- SNPX -0.02
- HTLD 0.04
- Stochastic Oscillator
- SNPX 31.02
- HTLD 40.82
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.